The Challenge
▫ Medical professionals do not have access to in vitro (laboratory) tools to objectively diagnose, estimate clinical severity, and treat patients suffering from epilepsy.
▫ This lack of precision contributes to one-third of epilepsy patients failing the first medication resulting in significant treatment delays, months to years of repeated trauma to the brain, and increased risk of cognitive impairment.
▫ NeuroDetect is developing machine learning-guided software that will allow medical professionals to create precision-guided biomarker profiles of patients suffering from epilepsy.
